Da­ta sug­gest gene, cell ther­a­py tri­al ini­ti­a­tions in Eu­rope lag be­hind North Amer­i­ca — here's why

Med­ical sci­ence has moved on from the one-size-fits-all ap­proach to the era of per­son­al­ized med­i­cine. Eu­ro­pean au­thor­i­ties ap­proved the world’s first-ever gene ther­a­py — GSK’s Strimvelis, a treat­ment for an in­or­di­nate­ly rare in­her­it­ed dis­or­der char­ac­ter­ized by a rav­aged im­mune sys­tem, in 2016. So far, the EMA has grant­ed the great­est num­ber of mar­ket­ing au­tho­riza­tions for ad­vanced ther­a­py med­i­c­i­nal prod­ucts (ATMPs) —or med­i­cines based on genes, tis­sues or cells — glob­al­ly. But da­ta sug­gest that the num­ber of ATMP clin­i­cal tri­als ini­ti­at­ed in Eu­rope has been eclipsed by ini­ti­a­tions in North Amer­i­ca in re­cent years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER